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Available online 12 December 2016Background: Syncope has been associated with increased risk of sudden cardiac arrest (SCA) in speciﬁc patient
populations, such as hypertrophic cardiomyopathy, heart failure, and long QT syndrome, but data are lacking
on the risk of SCA associated with syncope among patients with coronary artery disease (CAD), the most com-
mon cause of SCA. We investigated this association among CAD patients in the community.
Methods:All cases of SCA due to CADwere prospectively identiﬁed in Portland, Oregon (population approximate-
ly 1 million) as part of the Oregon Sudden Unexpected Death Study 2002–2015, and compared to geographical
controls. Detailed clinical information including history of syncope and cardiac investigations was obtained
from medical records.
Results: 2119 SCA cases (68.4 ± 13.8 years, 66.9% male) and 746 controls (66.7 ± 11.7 years, 67.0% male) were
included in the analysis. 143 (6.8%) of cases had documented syncope prior to the SCA. SCA cases with syncope
were N5 years older and hadmore comorbidities than other SCA cases. After adjusting for clinical factors and left
ventricular ejection fraction (LVEF), syncopewas associatedwith increased risk of SCA (OR 2.8; 95%CI 1.68–4.85).
When analysis was restricted to subjects with LVEF ≥50%, the risk of SCA associated with syncope remained
signiﬁcantly elevated (adjusted OR 3.1; 95%CI 1.68–5.79).
Conclusions: Syncopewas associatedwith increased risk of SCA in CAD patients evenwith preserved LV function.
These ﬁndings suggest a role for this clinical marker among patients with CAD and normal LVEF, a large sub-
group without any current means of SCA risk stratiﬁcation.







Syncope is a commonmedical problem, with a reported incidence of
6.2 per 1000 person-years in the general population [1], accounting for
about 1% of all emergency department visits [2]. Syncope can be the
manifestation of amultitude of clinical conditions ranging from relative-
ly benign to life-threatening. With a standardized diagnostic approach,
the underlying etiology can be determined in the majority of patients
[3]. However, clinical management of syncope can pose major chal-
lenges, with particular concern among both providers and patientster, Heart Institute, Advanced
e Blvd., Los Angeles, CA 90048,
eliability and freedom from biasregarding risk of future adverse clinical events, including sudden cardiac
arrest (SCA).
The prognosis of syncope varieswidely dependingon theunderlying
etiology [2,4]. Previous studies have demonstrated that patients with
cardiac etiologies for syncope have higher mortality rates compared to
patients with non-cardiac or unknown causes of syncope [1,5,6]. In
the presence of heart failure with reduced left ventricular (LV) function,
hypertrophic cardiomyopathy, or a primary electrical disease such as
long QT or Brugada syndrome, syncope predicts increased risk of SCA
[7–11]. However, there is a signiﬁcant lack of data regarding risk of
SCA associated with syncope in the broader population of patients
with coronary artery disease (CAD), which is the most common under-
lying cause of SCA [12].
In a large, ongoing community-based study of SCA in the US North-
west, we evaluated the association between syncope and SCA among
CAD patients, with the ability to incorporate clinical factors and cardiac
investigations performed prior to the SCA event. Additionally, we
27A.L. Aro et al. / International Journal of Cardiology 231 (2017) 26–30sought to determine whether assessment of LV function is helpful in
distinguishing syncope patients at high risk of SCA.2. Methods
2.1. Study population
The Oregon Sudden Unexpected Death Study (Oregon SUDS) is an ongoing,
population-based study that prospectively ascertains cases of out of hospital cardiac arrest
in the Portland, Oregon metropolitan region (catchment area of approximately one
million). Analysis is conducted using a case-control design. The methods of the study
have been previously described in detail [13,14]. Brieﬂy, subjects with an out-of-hospital
cardiac arrest were prospectively identiﬁed through three main sources: the emergency
medical response system (EMS), local hospital emergency rooms, and the county's
medical examiner's ofﬁce. All existing documents, including the EMS report, patient's
complete lifetime medical records, death certiﬁcate and autopsy report, if available,
were obtained for each case.
Based on this comprehensive information, in-house adjudication was performed by
three physicians in order to determine whether the case fulﬁlled pre-speciﬁed criteria
for SCA and CAD. Control subjects were concomitantly enrolled from the same geograph-
ical region and were required to have documented CAD. They were recruited from clinics
of participating health systems, from individuals receiving coronary angiography, from
patients transported by EMS for symptoms suggestive of coronary ischemia, and from
members of a local health maintenance organization. Medical records for each potential
control were reviewed in the same manner as the cases.
Subjects for the present analysiswere enrolled from February 1st 2002 to January 31st
2015, and were at least 18 years of age. Medical records were reviewed for baseline
demographic data and clinical history. A cardiologist analyzed archived 12-lead electro-
cardiograms (ECGs) performed prior and unrelated to the SCA event, if available, for the
presence of conduction disturbances, and resting heart rate, QRS duration and QTc-
interval (corrected according to the Bazett's formula) were measured. Heart rate and
QRS duration were obtained from automated ECG reports. QT-interval was measured
manually from the beginning of the QRS complex to the end of the T wave in lead V5
deﬁned by the tangent of the downslope of the T wave using a digital onscreen software
program (DataInf Measure; DataInf GmbH; Tübingen, Germany). Information on LV
ejection fraction (LVEF)was collected from archived imaging reports available in themed-
ical records. LVmass index, adjusted for body surface area,was calculated for subjectswith
necessary echocardiographic parameters available using the linear formula as recom-
mended by the American Society of Echocardiography [15]. Subjects with severe aortic
stenosis or hypertrophic cardiomyopathy were excluded from the echocardiographic
analysis. All included cases had their echocardiography performed prior and unrelated
to cardiac arrest (for 66% of cases, assessment of LV function was performed within two
years of arrest), and if multiple echocardiograms were available, the one closest to SCA
was included in the analysis. The majority of controls (81%) had echocardiograms
available that were performed within 2 years of ascertainment.Table 1
Demographics and clinical characteristics of subjects.
Cases Controls P value
(n = 2119) (n = 746)
Age (years) 68.4 ± 13.8 66.7 ± 11.7 0.003
Male 1417 (66.9%) 500 (67.0%) 0.94
Ethnicity 0.0004
White 1811 (86.5%) 656 (91.8%)
Black 154 (7.4%) 25 (3.5%)
Other 128 (6.1%) 34 (4.8%)
Syncope 143 (6.8%) 35 (4.7%) 0.04
Hypertension 1450 (68.4%) 554 (74.3%) 0.003
Diabetes 796 (37.6%) 236 (31.6%) 0.004
Pulmonary disease 685 (32.3%) 187 (25.1%) 0.0002
Chronic renal insufﬁciency 453 (21.4%) 111 (14.9%) 0.0001
History of myocardial infarction 716 (33.8%) 354 (47.4%) b0.0001
EF ≤ 35%a 212 (27.1%) 69 (12.0%) b0.0001
QTc (ms)b 451.7 ± 38.8 427.5 ± 32.7 b0.0001
Medicationc
Beta-blockers 878 (46.6%) 462 (66.1%) b0.0001
Antiarrhythmic 359 (19.0%) 67 (9.6%) b0.0001
Digoxin 247 (13.1%) 32 (4.6%) b0.0001
Data are presented as mean ± SD or n (%).
a EF information available for 783 cases and 574 controls.
b QTc information available for 601 cases and 563 controls.
c Medication information available for 1885 cases and 699 controls.2.2. Deﬁnitions
SCA was deﬁned as a sudden, unexpected pulseless condition of likely cardiac origin;
unwitnessed caseswere required to have been seen in a normal state of healthwithin 24h
of death [12]. Using pre-speciﬁed criteria, cases with chronic terminal illnesses, end-stage
heart failure orwith non-cardiac etiology for cardiac arrest, such as trauma, drugoverdose,
cerebrovascular accident or pulmonary embolism, were excluded during the adjudication
process. Both survivors and non-survivors of cardiac arrest were included as cases. For the
present study, SCA cases were required to have signiﬁcant established CAD; or, if they
were ≥50 years but with no documented CAD, were presumed to have CAD (in published
autopsy studies the proportion of subjects with CAD in this group has been N90%) [16].
Recruited controls had an established CAD aswell, but were required not to have a history
of cardiac arrest or sustained ventricular arrhythmias, thereby enabling the identiﬁcation
of risk factors speciﬁc to SCA as opposed to CAD.
Established CAD was deﬁned as having ≥50% stenosis in a major coronary artery, or a
history of myocardial infarction or coronary revascularization. Hypertension was identi-
ﬁed from clinical history or use of antihypertensive medication; diabetes mellitus was
deﬁned as documentation of diabetes in the medical records or by the use of insulin or
other hypoglycemic agent; chronic renal insufﬁciency as clinical history of chronic kidney
disease in the medical records or ongoing dialysis; and pulmonary disease as history of
asthma or chronic obstructive pulmonary disease (COPD), or medical therapy for these
conditions.
Information on syncope was systematically collected from the medical records of the
patients. According to guidelines, syncope is deﬁned as transient loss of consciousness
supposedly due to transient global cerebral hypoperfusion that is characterized by rapid
onset, short duration and spontaneous complete recovery [2]. Unconsciousness due to
other factors such as epileptic seizures, intoxication, or metabolic disorders such as hypo-
glycemiawas not classiﬁed as syncope, nor was pre-syncope that did not lead to complete
loss of consciousness.
This study was approved by the Institutional Review Boards of Cedars-Sinai Medical
Center, Oregon Health and Science University and all participating hospitals and health
systems.2.3. Statistical analysis
Independent-samples t-tests and Pearson's chi-square tests were used for bivariate
case-control and case-case comparisons for continuous and categorical variables, respec-
tively. A multivariable logistic regression model was used to estimate odds ratios (OR)
with 95% conﬁdence intervals (CI) for SCA risk associatedwith history of syncope. Adjust-
ments to the models weremade for covariates that differed between the groups. Age was
added as a continuous variable and race, hypertension, diabetes, history of COPD or
asthma, chronic renal insufﬁciency, use of beta-blockers, digoxin or antiarrhythmic
medication, and LVEF (b50% vs. ≥50%) were added as categorical variables. Separate
subgroup analysis according to LVEFwas also conducted among subjectswith information
available on LV function. Two-sided statistical tests were used, and P values ≤0.05 were
considered statistically signiﬁcant.
3. Results
3.1. Characteristics of SCA cases and controls
3074 subjects (2328 SCA cases, 746 controls with CAD) aged
≥18 years had medical records available for analysis. After excluding
209 cases without evidence of signiﬁcant CAD from the analysis, 2119
SCA cases remained in the ﬁnal analysis. Overall, 277 cases survived
to hospital discharge (16.1% of cases with resuscitation attempted).
The demographic characteristics of the subjects are presented in
Table 1. SCA cases were slightly older (68.4 ± 13.8 vs. 66.7 ±
11.7 years; p = 0.003) compared to controls, and less likely to be of
white European descent (86.5% vs. 91.8%, p b 0.001), but no difference
in sex distribution between the groups was observed (66.9% vs. 67.0%
male). Cases were more often diabetics and were more likely to have
chronic renal insufﬁciency, pulmonary disease and reduced LV function
than controls. Antiarrhythmic medication and digoxin were more
commonly used among cases, but beta-blocker medication was more
common among controls.
3.2. Syncope and risk of SCA according to LV function
143 (6.8%) SCA cases had experienced a documented episode of syn-
cope prior and unrelated to their cardiac arrest, compared to 35 (4.7%)
controls, with an unadjusted 1.5-fold risk of SCA (OR 1.5; 95% CI 1.01–
2.15; p= 0.05). In a multivariate model including age, race, hyperten-
sion, diabetes, chronic renal insufﬁciency, pulmonary disease, use of
beta-blockers, digoxin and antiarrhythmic medication together with
Table 2
Multivariable adjusted odds ratios (ORs) and 95% conﬁdence intervals (CI) for SCA associ-
ated with syncope, according to left ventricular function.
OR 95% CI P value
All subjectsa 2.8 1.68–4.85 0.0001
LVEF N35%b 2.9 1.59–5.01 0.0004
LVEF ≥50%c 3.1 1.68–5.79 0.0003
Adjusted for age, race, hypertension, diabetes, pulmonary disease, chronic renal insufﬁ-
ciency, beta-blockers, antiarrhythmic medication, digoxin and LVEF (LVEF for all subjects
only).
a 755 cases, 520 controls.
b 551 cases, 455 controls.
c 407 cases, 371 controls.
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Fig. 1 presents the risk of SCA associated with syncope according to
LVEF, and distribution of LVEF in these patients. When analysis was
restricted to subjects with normal LVEF ≥50%, 12.1% of cases and 4.6%
of controls had presented with syncope (p b 0.001), and after adjusting
for demographic and clinical variables the SCA risk associated with a
history of syncope remained signiﬁcant in this group (OR 3.1; 95% CI
1.68–5.79; p b 0.001) (Table 2).3.3. Comparison between cases and controls with history of syncope
In order to identify clinical factors associated with syncope that may
predict future SCA, we compared SCA cases with history of syncope to
controls that had experienced syncope but not cardiac arrest. SCA
cases with syncope were older (73.7 ± 13.1 vs. 67.5 ± 10.2 years, p =
0.01) than controls, but there were no signiﬁcant differences in race,
sex, hypertension, diabetes, pulmonary disease or renal insufﬁciency.
The proportion of patients with reduced LVEF ≤35% was larger among
cases with syncope compared to controls with syncope, but this ﬁnding
did not reach statistical signiﬁcance (27.7% vs. 12.0%, p=0.18). No signif-
icant difference in QRS duration was noted between the cases and con-
trols, but QTc interval was longer (462 ± 43 ms vs. 430 ± 42 ms, p =
0.002) among SCA cases with history of syncope. Cases with syncope
were also more likely to be on antiarrhythmic medication (28.4% vs.
5.9%, p=0.006) and digoxin (17.9% vs. 2.9%, p=0.03) compared to con-
trols with syncope, but there was no difference in beta-blocker use. In a
multivariablemodel including several demographic/clinical variables, an-
tiarrhythmic medications and LVEF, every 20 ms increase in QTc interval
among syncope patients was associated with 2.6-fold increased risk for
SCA (95% CI 1.12–5.87, p = 0.03), compared to 1.5-fold increased riskFig. 1.Association between left ventricular ejection fraction and sudden cardiac arrest in patien
who suffered future sudden cardiac arrest (SCA). B. Adjusted risk of SCA associated with synco(95% CI 1.34–1.70, p b 0.001) associated with 20 ms QTc prolongation
among patients without history of syncope.
3.4. Characterization of SCA cases with and without history of syncope
Table 3 demonstrates the characteristics of SCA cases with andwith-
out history of syncope. Cases with syncope were older and had higher
prevalence of hypertension, renal insufﬁciency, and history of atrial
ﬁbrillation, but there were no differences in LV function or LV mass
index between the groups. The prevalence of conduction abnormalities
and electrocardiographic characteristics of SCA cases with and without
syncope are also presented in Table 3. No signiﬁcant differences in
heart rate, QRS duration, QTc interval or conduction abnormalities
were observed. However, SCA cases with syncope were more likely to
have class I or III antiarrhythmic medications, but no signiﬁcant differ-
ences in the use of beta-blockers, digoxin, diuretics, ACE inhibitors or
Ca-channel blockers were noted between the cases with and without
syncope. In controls with andwithout history of syncope, no differences
in medication use were observed (data not shown).
4. Discussion
Syncope is often a difﬁcult clinical condition to evaluate andmanage,
with a large differential diagnosis ranging from benign conditions to
life-threatening diseases. Data has been lacking on the association
between syncope and SCA in the community. In this population-based
study, we addressed the risk of SCA associated with syncope in subjects
with CAD. Overall, 7% of patients who suffered SCA had sought medical
attention for syncope prior to their cardiac arrest. Syncope was a signif-
icant predictor of SCA in these patients independent of several clinical
confounding factors, suggesting the potential of syncope events as
clinical predictors of increased SCA risk in patients with CAD.Moreover,
when analysis was restricted to subjects with preserved LV function, a
sub-group for which there is a critical need to established newmethods
of risk stratiﬁcation, syncope remained associated with 3-fold risk of
SCA.
The prognostic signiﬁcance of syncope has varied depending on the
population studied. In the Framingham Heart Study general population
cohort, syncope from any cause was associated with 31% increase in
mortality. Cardiac syncope was associated with a two-fold risk of mor-
tality, while vasovagal syncope appeared to have a benign prognosis
[1]. A Danish registry study comparing 37,000 ﬁrst-time syncope
patients without previous comorbidities to 185,000 matched controls,
demonstrated only 6% increase in mortality associated with syncope,
but an increased risk of cardiovascular hospitalizations, stroke andts with syncope. A. Distribution of left ventricular ejection fraction (EF) in syncope patients
pe in patients with reduced and normal left ventricular function.
Table 3
Clinical, echocardiographic and electrocardiographic characteristics of SCA cases with and
without syncope.
Syncope No syncope P value
(n = 143) (n = 1976)
Age (years) 73.7 ± 13.1 68.0 ± 13.8 b0.0001
Male 91 (63.6%) 1326 (67.1%) 0.39
Ethnicity 0.62
White 120 (83.9%) 1691 (86.7%)
Black 12 (8.4%) 142 (7.3%)
Other 11 (7.7%) 117 (6.0%)
Hypertension 109 (76.2%) 1341 (67.9%) 0.04
Diabetes 53 (37.1%) 743 (37.6%) 0.90
Pulmonary disease 43 (30.1%) 642 (32.5%) 0.55
Chronic renal insufﬁciency 41 (28.7%) 412 (20.8%) 0.03
History of atrial ﬁbrillation 52 (36.4%) 424 (21.5%) b0.0001
Medication**
Beta-blockers 72 (53.7%) 806 (46.0%) 0.08
Antiarrhythmic 38 (28.4%) 321 (18.3%) 0.004
Digoxin 24 (17.9%) 223 (12.7%) 0.09
Diuretics 72 (53.7%) 817 (46.7%) 0.11
LVEF ≤35% 23 (27.7%) 189 (27.0%) 0.90
Left ventricular hypertrophya 28 (45.2%) 185 (41.8%) 0.68
Heart rate (bpm) 75.5 ± 17.1 79.1 ± 18.9 0.08
QRS (ms) 105.8 ± 31.4 103.0 ± 24.6 0.42
QTc (ms) 462.1 ± 43.1 450.7 ± 38.3 0.07
Cardiac conduction 0.83
Normal conduction 50 (54.4%) 488 (54.5%)
Low-grade conduction abnormalityb 12 (13.0%) 99 (11.0%)
High-grade conduction abnormalityc 30 (32.6%) 309 (34.5%)
Data are presented as mean ± SD or n (%). Information available on medications for 134
syncope and 1751 non-syncope cases, on LVEF for 83 syncope and 700 non-syncope
cases, on left ventricular hypertrophy for 62 syncope and 443 non-syncope cases, and
on electrocardiographic data for 90 syncope and 883 non-syncope cases.
a Deﬁned as echocardiographic LV mass index ≥110 g/m2 in women and ≥134 g/m2 in
men.
b First-degree atrioventricular block, isolated left anterior or posterior fascicular block,
or incomplete left/right bundle-branch block.
c Complete left/rightbundle-branchblock, intraventricular conductiondelay (QRS≥120ms)
or II- or III-degree atrioventricular block.
⁎⁎ Medication information available for 134 cases with syncope and 1751 no-syncope cases.
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with andwithout syncopematched for cardiovascular disease and other
important clinical variables did not identify syncope as an independent
risk factor for cardiac mortality or cardiovascular events; rather, prog-
nosis was determined by underlying cardiac comorbidities, especially
heart failure [18]. Several studies conducted among emergency depart-
ment patients have later suggested, that age and underlying cardiovas-
cular diseases instead of themechanismof syncope are related to future
hospitalizations andmortality [19–21]. In the present study, we also ob-
served that among SCA patients, those with a history of syncope were
signiﬁcantly older and had more comorbidities than SCA cases without
syncope. However, even after adjusting for clinical factors and LV func-
tion, syncope was associated with increased risk of SCA among the CAD
population.
In patients with heart failure and reduced LV systolic function, syn-
cope has been associatedwith increased risk of sudden death regardless
of the etiology of syncope [22]. However, to our knowledge the present
study is the ﬁrst to demonstrate that the association between syncope
and SCA is independent of LV systolic function. In fact, we observed a
three-fold increased risk of SCA also among patients with preserved
LV ejection fraction. These ﬁndings may have implications for the
process of improving risk stratiﬁcation in patients who suffer SCA
with preserved LVEF. The scientiﬁc literature has established that the
majority of SCA events (at least 50%) occur among patients with
preserved LVEF [23,24], yet current guidelines do not provide any
means of risk stratifying this large sub-group [25,26]. Patients with cor-
onary disease and syncope appear to be a special population in this
regard and the potential role of syncope as a clinical risk marker inpatients with preserved LVEF and coronary disease warrants further
evaluation.
Underlying etiologies of syncope vary depending on the group of pa-
tients studied. In younger age groups, vasovagal and neurally mediated
syncope are themost prevalent causes, but in older populations, cardiac
causes of syncope together with orthostatic hypotension and carotid
sinus hypersensitivity become more common [2]. When a cardiac dis-
ease condition or conduction abnormality is present, the suspicion for
a cardiac origin of syncope has to be high, and often further diagnostic
work-up, including electrophysiological study, are needed for the diag-
nosis and therapeutic decisions. However, this does notmean that every
syncopal episode in cardiac patients is due to bradycardia or ventricular
tachyarrhythmia. Even among subjects with a bundle-branch block and
history of syncope who are at high risk of developing atrioventricular
block, comprehensive evaluation including insertion of a loop recorder
revealed non-bradycardia related mechanisms in a signiﬁcant number
of patients [27]. Similar observations on competing etiologies for synco-
pe have beenmade in ICD trials demonstrating that not all syncopal ep-
isodes are due to poorly tolerated and self-limiting ventricular
arrhythmias even in this high-risk group. For example, the Sudden Car-
diac Death in Heart Failure Trial (SCD-HeFT) performed among heart
failure patients with reduced LVEF showed that appropriate ICD shocks
were more common in patients with syncope, yet the ICD did not re-
duce the mortality risk associated with syncope; nor did it protect
against syncope recurrences compared to amiodarone or placebo [7].
While the retrospective analysis of syncope in the present study pre-
cluded precise categorization of syncopal events, it is likely that
among SCA victims, non-arrhythmic and multifactorial mechanisms
are important contributors to syncope. These data are in accordance
with our ﬁnding that conduction abnormalities were not more preva-
lent in SCA cases with history of syncope compared to those without
documented syncopal episodes.
Identifying individuals at high risk of future adverse events andmor-
tality has been a focus of multiple prior studies, and several risk stratiﬁ-
cation tools have been developed in order to help in syncope risk
stratiﬁcation in emergency departments [28,29]. The present study
does not directly answer how to distinguish high-risk individuals with
syncope from those with better prognosis. However, syncope patients
with subsequent cardiac arrest were older and had a markedly longer
QTc interval than controlswith syncope. Even after adjusting for clinical
factors, medications and LVEF, QTc prolongation was strongly associat-
ed with SCA among syncope patients suggesting the potential utility
of incorporating QTc interval into the risk stratiﬁcation algorithms.
This is in accordance with previous observations from different popula-
tion samples linking QT prolongation with SCA [30,31]. Besides genetic
predisposition and QT prolonging medications, acquired comorbidities
including myocardial infarction and other structural heart disease can
cause prolongation of the QT interval [30,31]. It is thus possible that in
addition to vulnerability for ventricular arrhythmias caused by
prolonged repolarization, prolonged QT interval can reﬂect underlying
cardiac pathology or QT prolongingmedication associated with adverse
outcome in patients with syncope.
Strengths of the present study include the prospective
ascertainment of SCA cases and the community-based approach. Since
SCA is most often due to an acute or chronic manifestation of CAD, the
controls recruited in Oregon SUDS were CAD patients making the
observed differences between the groups likely to be speciﬁc to SCA.
However, several limitations should also be considered while
interpreting the results. Although SCA cases were prospectively and
uniformly collected, since SCA can often be the ﬁrst manifestation of
cardiac disease, medical records were not uniformly available for
every case leading to some potential for bias. This is especially true in
the subgroup with echocardiographic data available, a subset that is
more likely to have cardiovascular disease or risk factors. Another
limitation is the retrospective classiﬁcation of syncope. During the
adjudication process, information on syncope was systematically and
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mechanism of syncope or its timing relatively to cardiac arrest could
not be reliably addressed. Also, our reported occurrence of syncope is
likely to underestimate prevalence, since all patients with syncope
may not seekmedical attention for their symptoms. Finally, it is possible
that for some patients with syncope a timely medical intervention may
have prevented future SCA.
5. Conclusion
These ﬁndings demonstrate that syncope is a signiﬁcant risk factor
for SCA among CAD patients even with preserved LV systolic function,
highlighting the need for comprehensive evaluation and risk assess-
ment of these patients. The current lack of effective SCA risk stratiﬁca-
tion in patients with preserved LVEF represents a signiﬁcant and
critical knowledge gap, and these ﬁndings suggest that a renewed
focus on comprehensive investigation of the potential role of syncope
as a clinical risk marker is warranted.
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